Allegra d substitute

Evidence that an individual has tampered with a drug or alcohol test during employee’s employment with the District. Information that an employee has caused, contributed to, or been involved in an accident while at work. The occurrence of an accident, while at work or working, in and of itself shall not constitute reasonable suspicion. However, individual circumstances of an accident, including, but not limited to, the nature and extent of the employee’s involvement in the accident, may be considered as one allegra d substitute element of reasonable suspicion. Evidence that an employee has used, possessed, sold, solicited, or transferred drugs while working or while on District premises or while operating District vehicles, machinery or equipment. If testing is conducted based on reasonable suspicion, the District will immediately document the circumstances that formed the basis of determination to warrant the testing. The original documentation shall be kept confidential by the District pursuant to this policy and shall be retained for at least one (1) year. A copy of this documentation shall be given to the employee upon written request. Follow-up - If an employee, in the course of employment, has a confirmed positive drug or alcohol test and subsequently accesses the Employee Assistance Program (EAP) for drug-related and/or alcohol-related problems or enters an alcohol and drug rehabilitation allegra goodman ny times program, the District will require the employee to submit to a drug and/or alcohol test upon completion of the program as follow-up to such program, and on a quarterly basis, for two (2) years thereafter. DRUG TESTING PROCEDURE All specimen allegra d substitute collection and testing for drugs shall be conducted in accordance with Sections 440. The District may test allegra d substitute for any or all of the following: Alcohol Amphetamines Cannabinoids allegra with oj cocaine Phencyclidine Methaqualone Opiates Barbiturates Benzodiazepines Methadone Propoxyphene 2. The initial screen for all drugs shall use an immunoassay. The initial test for alcohol shall be an enzyme oxidation methodology. When first screening specimens, all levels equal to or exceeding the following shall be reported as allegra d substitute positive: Alcohol . 05g% (by blood) Amphetamines 1000 ng/ml Cannabinoids 50 ng/ml Cocaine allegra d substitute 300 ng/ml Phencyclidine 25 ng/ml Methaqualone allegra d substitute 300 ng/ml Opiates 300 ng/ml Barbiturates 300 ng/ml Benzodiazepines 300 allegra d substitute ng/ml Methadone 300 ng/ml Propoxyphene 300 ng/ml These levels will remain in effect until such time as they allegra d substitute are revised by Federal Legislation or State allegra d substitute Statute. All new levels will allegra d substitute become effective on the date specified within the related legislation. All specimens identified as positive on the initial tests shall be confirmed using a second test. A gas chromatography/mass spectrometry (GC/MS) test, or an equivalent or more accurate scientifically accepted method approved by the State or Federal government will be used for the confirmation test for narcotics. The confirmation test for alcohol will be gas chromatography. All confirmations shall be done by quantitative analysis. When confirming initial results, all levels equal to or exceeding the following shall be reported as positive: Alcohol . 05g% (by blood) Amphetamines 500 ng/ml Cannabinoids 15 ng/ml Cocaine allegra d substitute 150 ng/ml Phencyclidine 25 ng/ml Methaqualone 150 ng/ml Opiates 300 ng/ml allegra side effects for children barbiturates 150 ng/ml Benzodiazepines 150 ng/ml Methadone 150 ng/ml Propoxyphene 150 ng/ml These levels will remain in effect until such time as they are revised by Federal Legislation or State Statute. All new levels will become effective on the date specified within the related legislation. The laboratory shall report test results to a medical review officer (MRO) chosen by the District to act on its behalf. These results shall be reported within seven (7) working days after receipt of the specimen by the laboratory. The laboratory shall transmit results to the medical review officer (MRO) in a manner designed to ensure confidentiality of the information. All records pertaining to a given specimen shall be retained by the laboratory for a minimum of two (2) years, unless the District or the employee requests that records be retained for a longer period of time.